3 months versus 10.4 months for chemotherapy and 39.2 months versus 18.4 months for surgery). HWE, linkage disequilibrium and haplotypes TGFB1 and VEGF For TGFB1, one of the three SNPs (rs1800469C>T, rs1800470T>C and rs1800471G>C) was not in HWE (P < 0.05 for rs1800469C>T), suggesting a possible selection bias, but none of the VEGF SNPs (rs833061T>C,

rs2010963G>C and rs3025039C>T) departed from HWE (P > 0.05 for all). None of the pairs of TGFB1 or VEGF SNPs were in high linkage disequilibrium (i.e., r2 AUY-922 manufacturer between 0.039 and 0.541, Tideglusib in vivo all <0.08). Only four TGFB1 haplotypes and five VEGF haplotypes had an allele frequency of >0.05 (C-T-G, 0.570; C-C-G, 0.190; T-C-G, 0.167 and C-C-C, 0.063 for TGFB1 and C-G-C, 0.344; T-C-C, 0.287; T-G-C, 0.192; C-G-T, 0.072 and T-C-T, 0.051 for VEGF). Because of the small sample size, we did not calculate the diplotypes. TGFB1 and VEGF genotype distributions and overall survival When all gastric cancer patients were analyzed for overall survival, no significant difference was found in the distributions of mean survival time by genotypes for any of the polymorphisms studied. Because there were few participants in the

minor homozygous variant groups, we combined the heterozygous and minor variant homozygous genotypes together for additional analysis, assuming a dominant genetic model, but there was still no association between detected polymorphisms and overall survival (see Additional BTK inhibitor file 1). Furthermore, when the gastric cancer

patients were stratified by age, sex, ethnicity, and metastatic status, no difference in the distribution according to mean survival time by the six SNPs was found among the subgroups (see Additional file 1). TGFB1 6-phosphogluconolactonase and VEGF genotype distributions and 1-and 2-year survivals Because the prognosis is generally poor in advanced cases of gastric cancer, median survival rarely approaches 1 or 2 years [2]. In the present study, most of the cases were stage IV (101/167) with a median survival time of only 16.2 months (95% CI, 12.8–24.9). Therefore, we also calculated the 1-year and 2-year survival rates for patients with different genotypes (see Additional file 2). The overall 1-year and 2-year survivals for all patients were 51.5% and 22.1%, respectively. Although there were no significant differences in the survival rates between most genotypes, patients with TGFB1 + 915CG/CC genotypes had better 1-year and 2-year survival than those with the GG genotype (adjusted HR, 2.13; 95% CI, 0.76–6.01; P = 0.122 and adjusted HR, 3.06; 95% CI, 1.09–8.62; P = 0.034, respectively) (Figure 1). Furthermore, patients heterozygous for VEGF -634CG also had a better 1-year survival rate (adjusted HR, 2.08; 95% CI, 1.03–4.22; P = 0.042) than those with the VEGF -634 GG genotype. Figure 1 Cumulative survival functions of the genotypes TGFB1 +915 G>C (rs1800471) and VEGF -634G>C (rs2010963).